Inhibition of angiogenesis and invasion in malignant gliomas

References

• World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the Nervous System. Kleihues P, Cavenee W (Eds). IARC Press, Lyon, France (2000).
   Google Scholar
• Stupp R, Mason W, van den Bent M et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Wong E, Hess K, Gleason M et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17(8), 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel R. Angiogenesis as a therapeutic target. Nature438(7070), 967–974 (2005).
   PubMed Web of Science ®Google Scholar
• Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol.2(11), 562–577 (2005).
   PubMedGoogle Scholar
• Vredenburgh J, Desjardins A, Herndon JE et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res.13(4), 1253–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Kerbel R, Yu J, Tran J et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev.20(1–2), 79–86 (2001).
   PubMed Web of Science ®Google Scholar
• Sweeney C, Miller K, Sledge GJ. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol. Med.9(1), 24–29 (2003).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia2(4), 306–314 (2000).
   PubMed Web of Science ®Google Scholar
• Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer3(7), 489–501 (2003).
   PubMed Web of Science ®Google Scholar
• Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature438(7070), 937–945 (2005).
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med.6(4), 389–395 (2000).
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature438(7070), 932–936 (2005).
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin L. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer3(6), 401–410 (2003).
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82(1), 4–6 (1990).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86(3), 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg R. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Naumov G, Bender E, Zurakowski D et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl Cancer Inst.98(5), 316–325 (2006).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285(21), 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J. Natl Cancer Inst.48(2), 347–356 (1972).
   PubMed Web of Science ®Google Scholar
• Brem S, Tsanaclis A, Gately S, Gross J, Herblin W. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer70(11), 2673–2680 (1992).
   PubMed Web of Science ®Google Scholar
• Leon S, Folkerth R, Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer77(2), 362–372 (1996).
   PubMed Web of Science ®Google Scholar
• Burger P, Vogel F, Green S, Strike T. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer56(5), 1106–1111 (1985).
   PubMed Web of Science ®Google Scholar
• Benjamin L, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest.103(2), 159–165 (1999).
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science284(5422), 1994–1998 (1999).
   PubMed Web of Science ®Google Scholar
• Vajkoczy P, Farhadi M, Gaumann A et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J. Clin. Invest.109(6), 777–785 (2002).
   PubMed Web of Science ®Google Scholar
• Zagzag D, Hooper A, Friedlander D et al.In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp. Neurol.159(2), 391–400 (1999).
   PubMed Web of Science ®Google Scholar
• Zagzag D, Zhong H, Scalzitti J, Laughner E, Simons J, Semenza G. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer88(11), 2606–2618 (2000).
   PubMed Web of Science ®Google Scholar
• Zagzag D, Amirnovin R, Greco MA et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab. Invest.80(6), 837–849 (2000).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature407(6801), 249–257 (2000).
   PubMed Web of Science ®Google Scholar
• Brat D, Castellano-Sanchez A, Kaur B, Van Meir E. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv. Anat. Pathol.9(1), 24–36 (2002).
   PubMed Web of Science ®Google Scholar
• Kaur B, Khwaja F, Severson E, Matheny S, Brat D, Van Meir E. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncology7(2), 134–153 (2005).
   PubMed Web of Science ®Google Scholar
• Fischer I, Gagner J, Law M, Newcomb E, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol.15(4), 297–310 (2005).
   PubMed Web of Science ®Google Scholar
• Kargiotis O, Rao J, Kyritsis A. Mechanisms of angiogenesis in gliomas. J. Neurooncol.78(3), 281–293 (2006).
   PubMed Web of Science ®Google Scholar
• Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma – a target for antitumor therapy? Crit. Rev. Oncol. Hematol.59(3), 181–193 (2006).
   PubMed Web of Science ®Google Scholar
• Reiss Y, Machein M, Plate K. The role of angiopoietins during angiogenesis in gliomas. Brain Pathol.15(4), 311–317 (2005).
   PubMed Web of Science ®Google Scholar
• Dunn I, Heese O, Black P. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J. Neurooncol.50(1–2), 121–137 (2000).
   PubMed Web of Science ®Google Scholar
• Kaur B, Tan C, Brat D, Post D, Van Meir E. Genetic and hypoxic regulation of angiogenesis in gliomas. J. Neurooncol.70(2), 229–243 (2004).
   PubMed Web of Science ®Google Scholar
• Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett.235(1), 1–10 (2006).
   PubMed Web of Science ®Google Scholar
• Pore N, Liu S, Haas-Kogan D, O’Rourke D, Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res.63(1), 236–241 (2003).
   PubMed Web of Science ®Google Scholar
• Guo W, Giancotti F. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol.5(10), 816–826 (2004).
   PubMed Web of Science ®Google Scholar
• Lakka S, Gondi C, Rao J. Proteases and glioma angiogenesis. Brain Pathol.15(4), 327–341 (2005).
   PubMed Web of Science ®Google Scholar
• Lakka SS, Gondi CS, Dinh DH et al. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J. Biol. Chem.280(23), 21882–21892 (2005).
   PubMed Web of Science ®Google Scholar
• Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp. Cell Res.312(5), 651–658 (2006).
   PubMed Web of Science ®Google Scholar
• Wang D, Anderson J, Gladson C. The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol.15(4), 318–326 (2005).
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-oncology7(4), 452–464 (2005).
   PubMed Web of Science ®Google Scholar
• Bertolini F, Shaked Y, Mancuso P, Kerbel R. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer6(11), 835–845 (2006).
   PubMed Web of Science ®Google Scholar
• Coussens L, Werb Z. Inflammation and cancer. Nature420(6917), 860–867 (2002).
   PubMed Web of Science ®Google Scholar
• Grunewald M, Avraham I, Dor Y et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell124(1), 175–189 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan R, Psaila B, Lyden D. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev.25(4), 521–529 (2006).
   PubMed Web of Science ®Google Scholar
• Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med.9(6), 702–712 (2003).
   PubMed Web of Science ®Google Scholar
• Rege T, Fears C, Gladson C. Endogenous inhibitors of angiogenesis in malignant gliomas: nature’s antiangiogenic therapy. Neuro-oncology7(2), 106–121 (2005).
   PubMed Web of Science ®Google Scholar
• Gagner J, Law M, Fischer I, Newcomb E, Zagzag D. Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol.15(4), 342–363 (2005).
   PubMed Web of Science ®Google Scholar
• de Bouard S, Guillamo J. Angiogenesis and anti-angiogenic strategies for glioblastoma. Bull. Cancer92(4), 360–372 (2005).
   Google Scholar
• Kieran M. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat. Res.117, 337–349 (2004).
   PubMedGoogle Scholar
• Jain R, Di Tomaso E, Duda DG et al. Angiogenesis in brain tumors. Nat. Rev. Neurosci.8, 610–622 (2007).
   PubMed Web of Science ®Google Scholar
• Purow B, Fine H. Antiangiogenic therapy for primary and metastatic brain tumors. Hematol. Oncol. Clin. North Am.18(5), 1161–1181 (2004).
   PubMedGoogle Scholar
• Plate K, Breier G, Weich H, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature359(6398), 845–848 (1992).
   PubMed Web of Science ®Google Scholar
• Plate K. Mechanisms of angiogenesis in the brain. J. Neuropathol. Exp. Neurol.58(4), 313–320 (1999).
   PubMed Web of Science ®Google Scholar
• Plate K, Breier G, Weich H, Mennel H, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer59(4), 520–529 (1994).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett.580(12), 2879–2887 (2006).
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol. Divers.10(4), 515–527 (2006).
   PubMed Web of Science ®Google Scholar
• Ellis L. The role of neuropilins in cancer. Mol. Cancer Ther.5(5), 1099–1107 (2006).
   PubMed Web of Science ®Google Scholar
• Forsythe J, Jiang B, Iyer N et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol.16(9), 4604–4613 (1996).
   PubMed Web of Science ®Google Scholar
• Hicklin D, Ellis L. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res.55(20), 4575–4580 (1995).
   PubMed Web of Science ®Google Scholar
• Jiang B, Zheng J, Aoki M, Vogt P. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl Acad. Sci. USA97(4), 1749–1753 (2000).
   PubMed Web of Science ®Google Scholar
• Woods S, McGlade C, Guha A. Phosphatidylinositol 3´-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells. Neuro-oncology4(4), 242–252 (2002).
   Google Scholar
• Maity A, Pore N, Lee J, Solomon D, O’Rourke D. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3´-kinase and distinct from that induced by hypoxia. Cancer Res.60(20), 5879–5886 (2000).
   PubMed Web of Science ®Google Scholar
• Guo P, Hu B, Gu W et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol.162(4), 1083–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Tsai J, Goldman C, Gillespie G. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg.82(5), 864–873 (1995).
   PubMed Web of Science ®Google Scholar
• Wang D, Huang H, Kazlauskas A, Cavenee W. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res.59(7), 1464–1472 (1999).
   PubMed Web of Science ®Google Scholar
• Cheng S, Huang H, Nagane M et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA93(16), 8502–8507 (1996).
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF as a therapeutic target in cancer. Oncology69(Suppl. 3), 11–16 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan K, Gerber H, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov.3(5), 391–400 (2004).
   PubMed Web of Science ®Google Scholar
• Gerber H, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res.65(3), 671–680 (2005).
   PubMed Web of Science ®Google Scholar
• Im S, Gomez-Manzano C, Fueyo J et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res.59(4), 895–900 (1999).
   PubMed Web of Science ®Google Scholar
• Lee C, Heijn M, di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res.60(19), 5565–5570 (2000).
   PubMed Web of Science ®Google Scholar
• Kozin S, Boucher Y, Hicklin D, Bohlen P, Jain R, Suit H. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res.61(1), 39–44 (2001).
   PubMed Web of Science ®Google Scholar
• Kunkel P, Ulbricht U, Bohlen P et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res.61(18), 6624–6628 (2001).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Hjelmeland A, Keir S et al. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res.66(17), 8722–8730 (2006).
   PubMed Web of Science ®Google Scholar
• Albert D, Tapang P, Magoc T et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther.5(4), 995–1006 (2006).
   PubMed Web of Science ®Google Scholar
• Goudar R, Shi Q, Hjelmeland M et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther.4(1), 101–112 (2005).
   PubMed Web of Science ®Google Scholar
• Traxler P, Allegrini P, Brandt R et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res.64(14), 4931–4941 (2004).
   PubMed Web of Science ®Google Scholar
• Jones-Bolin S, Zhao H, Hunter K, Klein-Szanto A, Ruggeri B. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther.5(7), 1744–1753 (2006).
   PubMed Web of Science ®Google Scholar
• Fong T, Shawver L, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res.59(1), 99–106 (1999).
   PubMed Web of Science ®Google Scholar
• Ma J, Li S, Reed K, Guo P, Gallo J. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J. Pharmacol. Exp. Ther.305(3), 833–839 (2003).
   PubMed Web of Science ®Google Scholar
• Jane E, Premkumar D, Pollack I. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J. Pharmacol. Exp. Ther.319(3), 1070–1080 (2006).
   PubMed Web of Science ®Google Scholar
• Farhadi M, Capelle H, Erber R, Ullrich A, Vajkoczy P. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J. Neurosurg.102(2), 363–370 (2005).
   PubMed Web of Science ®Google Scholar
• Schueneman A, Himmelfarb E, Geng L et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res.63(14), 4009–4016 (2003).
   PubMed Web of Science ®Google Scholar
• Damiano V, Melisi D, Bianco C et al. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin. Cancer Res.11(15), 5639–5644 (2005).
   PubMed Web of Science ®Google Scholar
• Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.64(1), 33–37 (2006).
   PubMed Web of Science ®Google Scholar
• Rich J, Sathornsumetee S, Keir S et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res.11(22), 8145–8157 (2005).
   PubMed Web of Science ®Google Scholar
• Goldbrunner R, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn J. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery55(2), 426–432; discussion 432 (2004).
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA99(17), 11393–11398 (2002).
   PubMed Web of Science ®Google Scholar
• Wachsberger P, Burd R, Cardi C et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int. J. Radiat. Oncol. Biol. Phys.67(5), 1526–1537 (2007).
   PubMed Web of Science ®Google Scholar
• Jain R, Duda D, Clark J, Loeffler J. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol.3(1), 24–40 (2006).
   PubMedGoogle Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25, 4722–4729 (2007).
   Google Scholar
• Escudier B, Eisen T, Stadler W et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer G, Hutson TE, Tomczak P et al. Sunitinib versus interferon alpha in metastatic renal cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Conrad C, Friedman H, Reardon D et al. A Phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Presented at: The ASCO Annual Meeting. New Orleans, LA, USA, 5–8 June 2004.
   Google Scholar
• Reardon D, Friedman H, Brada M et al. A Phase I/II trial of PTK 787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Presented at: The Society for Neuro-Oncology Annual Meeting. Toronto, Canada, 18–21 November 2004.
   Google Scholar
• Drevs J, Zirrgiebel U, Schmidt-Gersbach C et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two Phase I trials. Ann. Oncol.16(4), 558–565 (2005).
   PubMed Web of Science ®Google Scholar
• Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist11(7), 753–764 (2006).
   PubMed Web of Science ®Google Scholar
• Batchelor T, Sorensen A, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes A, Van Oosterom A et al. Multicentre Phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC: NDDG/BTG Intergroup Study. Presented at: The ASCO Annual Meeting. New Orleans, LA, USA, 5–8 June 2004.
   Google Scholar
• van den Bent M, Brandes A, Frenay M et al. Multicentre Phase II study of imatinib mesylate (Gleevec®) in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): an EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. Presented at: The ASCO Annual Meeting. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar
• Wen P, Yung W, Lamborn K et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin. Cancer Res.12(16), 4899–4907 (2006).
   PubMed Web of Science ®Google Scholar
• Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol.16(10), 1702–1708 (2005).
   PubMed Web of Science ®Google Scholar
• Coomber B. Suramin inhibits C6 glioma-induced angiogenesis in vitro. J. Cell. Biochem.58(2), 199–207 (1995).
   Google Scholar
• D’Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA91(9), 4082–4085 (1994).
   PubMed Web of Science ®Google Scholar
• Gagliardi A, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins D. Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother. Pharmacol.41(2), 117–124 (1998).
   PubMed Web of Science ®Google Scholar
• Takano S, Gately S, Engelhard H, Tsanaclis A, Brem S. Suramin inhibits glioma cell proliferation in vitro and in the brain. J. Neurooncol.21(3), 189–201 (1994).
   PubMed Web of Science ®Google Scholar
• Fine H, Figg W, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol.18(4), 708–715 (2000).
   PubMed Web of Science ®Google Scholar
• Fine H, Wen P, Maher E et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J. Clin. Oncol.21(12), 2299–2304 (2003).
   PubMed Web of Science ®Google Scholar
• Marx G, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol.54(1), 31–38 (2001).
   PubMed Web of Science ®Google Scholar
• Kesari S, Schiff D, Henson JW et al. Phase II study of temozolomide, thalidomide and celecoxib for newly-diagnosed glioblastoma in adults. Neuro-Oncology (2007) (In Press).
   Google Scholar
• Chang S, Lamborn K, Malec M et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.60(2), 353–357 (2004).
   PubMed Web of Science ®Google Scholar
• Grossman S, Phuphanich S, Lesser G et al. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J. Clin. Oncol.19(13), 3260–3266 (2001).
   PubMed Web of Science ®Google Scholar
• Laterra J, Grossman S, Carson K, Lesser G, Hochberg F, Gilbert M. Suramin and radiotherapy in newly diagnosed glioblastoma: Phase 2 NABTT CNS Consortium study. Neuro-oncology6(1), 15–20 (2004).
   PubMed Web of Science ®Google Scholar
• Chi A, Wen P. Inhibiting kinases in malignant gliomas. Expert Opin. Ther. Targets11(4), 473–496 (2007).
   PubMed Web of Science ®Google Scholar
• Wen P, Kesari S, Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev. Anticancer Ther.6(5), 733–754 (2006).
   PubMed Web of Science ®Google Scholar
• Nabors L, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol.25, 1651–1657 (2007).
   Google Scholar
• Reardon D, Fink K, Nabors B et al. Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974–009. Presented at: The ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Stupp R, Goldbrunner R, Neyns B et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). Presented at: The ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Reardon D, Quinn J, Vredenburgh J et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer103(2), 329–338 (2005).
   PubMed Web of Science ®Google Scholar
• Levin V, Giglio P, Puduvalli V et al. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J. Neurooncol.78(1), 85–90 (2006).
   PubMed Web of Science ®Google Scholar
• Solomon S, McMurray J, Pfeffer M et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352(11), 1071–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest.105(8), 1045–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Bello L, Carrabba G, Giussani C et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res.61(20), 7501–7506 (2001).
   PubMed Web of Science ®Google Scholar
• Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res.63(15), 4342–4346 (2003).
   PubMed Web of Science ®Google Scholar
• Man S, Bocci G, Francia G et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res.62(10), 2731–2735 (2002).
   PubMed Web of Science ®Google Scholar
• Kamen B, Rubin E, Aisner J, Glatstein E. High-time chemotherapy or high time for low dose. J. Clin. Oncol.18(16), 2935–2937 (2000).
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield C, Kraling B et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res.60(7), 1878–1886 (2000).
   PubMed Web of Science ®Google Scholar
• Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol.220(4), 545–554 (2003).
   PubMed Web of Science ®Google Scholar
• Kerbel R, Kamen B. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer4(6), 423–436 (2004).
   PubMed Web of Science ®Google Scholar
• Klement G, Huang P, Mayer B et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res.8(1), 221–232 (2002).
   PubMed Web of Science ®Google Scholar
• Stoll B, Migliorini C, Kadambi A, Munn L, Jain R. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood102(7), 2555–2561 (2003).
   PubMed Web of Science ®Google Scholar
• Vacca A, Iurlaro M, Ribatti D et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood94(12), 4143–4155 (1999).
   PubMed Web of Science ®Google Scholar
• Kong D, Lee J, Kim W et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol. Rep.16(5), 1117–1121 (2006).
   PubMed Web of Science ®Google Scholar
• Kieran MW, Turner CD, Rubin JB et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J. Pediatr. Hematol. Oncol.27, 573–581 (2005).
   PubMed Web of Science ®Google Scholar
• Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J. Neurooncol.27(2), 149–155 (1996).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Rieger J, Steinbach J, Nagele T, Dichgans J, Weller M. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J. Neurooncol.71(3), 295–299 (2005).
   PubMed Web of Science ®Google Scholar
• Kesari S, Schiff D, Doherty L et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-oncology9(3), 354–363 (2007).
   PubMed Web of Science ®Google Scholar
• Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology30(9), 907–911 (1980).
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J. Neurosurg.66(6), 865–874 (1987).
   PubMed Web of Science ®Google Scholar
• Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol.23(10), 2411–2422 (2005).
   PubMed Web of Science ®Google Scholar
• Salhia B, Tran NL, Symons M, Winkles JA, Rutka JT, Berens ME. Molecular pathways triggering glioma cell invasion. Expert Rev. Mol. Diagn.6(4), 613–626 (2006).
   PubMed Web of Science ®Google Scholar
• Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell. Mol. Life Sci.64(4), 458–478 (2007).
   PubMed Web of Science ®Google Scholar
• Newton HB. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness. Expert Rev. Anticancer Ther.4(5), 803–821 (2004).
   PubMedGoogle Scholar
• Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol.21(8), 1624–1636 (2003).
   PubMed Web of Science ®Google Scholar
• Gunia S, Hussein S, Radu DL et al. CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma. Clin. Exp. Metastasis17(3), 221–230 (1999).
   Google Scholar
• Murai T, Miyazaki Y, Nishinakamura H et al. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J. Biol. Chem.279(6), 4541–4550 (2004).
   PubMed Web of Science ®Google Scholar
• Sasaki H, Yoshida K, Ikeda E et al. Expression of the neural cell adhesion molecule in astrocytic tumors: an inverse correlation with malignancy. Cancer82(10), 1921–1931 (1998).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Izumoto S, Fujimoto Y, Maruno M, Ito Y, Yoshimine T. Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion. J. Clin. Pathol.58(2), 166–171 (2005).
   PubMed Web of Science ®Google Scholar
• Izumoto S, Ohnishi T, Arita N, Hiraga S, Taki T, Hayakawa T. Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Cancer Res.56(6), 1440–1444 (1996).
   Google Scholar
• Asano K, Duntsch CD, Zhou Q et al. Correlation of N-cadherin expression in high grade gliomas with tissue invasion. J. Neurooncol.70(1), 3–15 (2004).
   PubMed Web of Science ®Google Scholar
• Uhm JH, Gladson CL, Rao JS. The role of integrins in the malignant phenotype of gliomas. Front. Biosci.4, E188–E199 (1999).
   PubMedGoogle Scholar
• Riemenschneider MJ, Mueller W, Betensky RA, Mohapatra G, Louis DN. In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am. J. Pathol.167(5), 1379–1387 (2005).
   Google Scholar
• Taga T, Suzuki A, Gonzalez-Gomez I et al. α v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer98(5), 690–697 (2002).
   PubMed Web of Science ®Google Scholar
• Naldini L, Tamagnone L, Vigna E et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J.11(13), 4825–4833 (1992).
   PubMed Web of Science ®Google Scholar
• Zhang X, Fei Z, Bu X et al. Expression and significance of urokinase type plasminogen activator gene in human brain gliomas. J. Surg. Oncol.74(2), 90–94 (2000).
   Google Scholar
• Bhattacharya A, Lakka SS, Mohanam S, Boyd D, Rao JS. Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin. Cancer Res.7(2), 267–276 (2001).
   PubMedGoogle Scholar
• Gondi CS, Lakka SS, Yanamandra N et al. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res.64(12), 4069–4077 (2004).
   PubMed Web of Science ®Google Scholar
• Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol.50(2), 87–100 (2004).
   PubMed Web of Science ®Google Scholar
• Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin. Ther. Targets7(3), 385–397 (2003).
   PubMed Web of Science ®Google Scholar
• Purcell WT, Rudek MA, Hidalgo M. Development of matrix metalloproteinase inhibitors in cancer therapy. Hematol. Oncol. Clin. North Am.16(5), 1189–1227 (2002).
   Google Scholar
• Nakada M, Okada Y, Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front. Biosci.8, E261–E269 (2003).
   PubMed Web of Science ®Google Scholar
• Sawaya R, Go Y, Kyritisis AP et al. Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo. Biochem. Biophys. Res. Commun.251(2), 632–636 (1998).
   Google Scholar
• Forsyth PA, Wong H, Laing TD et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer79(11–12), 1828–1835 (1999).
   PubMed Web of Science ®Google Scholar
• Sawaya RE, Yamamoto M, Gokaslan ZL et al. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin. Exp. Metastasis14(1), 35–42 (1996).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ishida E, Shimada K et al. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab. Invest.85(2), 165–175 (2005).
   PubMed Web of Science ®Google Scholar
• Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab. Invest.84(1), 8–20 (2004).
   PubMed Web of Science ®Google Scholar
• Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, Rosenblum ML. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J. Neurosurg.83(2), 285–290 (1995).
   Google Scholar
• Rempel SA, Rosenblum ML, Mikkelsen T et al. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res.54(23), 6027–6031 (1994).
   PubMed Web of Science ®Google Scholar
• Sivaparvathi M, Sawaya R, Wang SW et al. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin. Exp. Metastasis13(1), 49–56 (1995).
   PubMed Web of Science ®Google Scholar
• Strojnik T, Kos J, Zidanik B, Golouh R, Lah T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res.5(3), 559–567 (1999).
   PubMed Web of Science ®Google Scholar
• Yanamandra N, Gumidyala KV, Waldron KG et al. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene23(12), 2224–2230 (2004).
   PubMedGoogle Scholar
• Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene23(52), 8486–8496 (2004).
   PubMed Web of Science ®Google Scholar
• Fukuda ME, Iwadate Y, Machida T et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res.65(12), 5190–5194 (2005).
   PubMed Web of Science ®Google Scholar
• Flannery T, McQuaid S, McGoohan C et al. Cathepsin S expression: an independent prognostic factor in glioblastoma tumours – a pilot study. Int. J. Cancer119(4), 854–860 (2006).
   PubMed Web of Science ®Google Scholar
• Zajc I, Hreljac I, Lah T. Cathepsin L affects apoptosis of glioblastoma cells: a potential implication in the design of cancer therapeutics. Anticancer Res.26(5A), 3357–3364 (2006).
   PubMed Web of Science ®Google Scholar
• Bjarnason JB, Fox JW. Snake venom metalloendopeptidases: reprolysins. Methods Enzymol.248, 345–368 (1995).
   PubMed Web of Science ®Google Scholar
• Wildeboer D, Naus S, Amy Sang QX, Bartsch JW, Pagenstecher A. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J. Neuropathol. Exp. Neurol.65(5), 516–527 (2006).
   PubMed Web of Science ®Google Scholar
• Kodama T, Ikeda E, Okada A et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am. J. Pathol.165(5), 1743–1753 (2004).
   PubMed Web of Science ®Google Scholar
• Held-Feindt J, Paredes EB, Blomer U et al. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int. J. Cancer118(1), 55–61 (2006).
   Google Scholar
• Zheng X, Jiang F, Katakowski M et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci.98(5), 674–684 (2007).
   PubMed Web of Science ®Google Scholar
• Hecker TP, Grammer JR, Gillespie GY, Stewart J Jr, Gladson CL. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res.62(9), 2699–2707 (2002).
   PubMed Web of Science ®Google Scholar
• Zagzag D, Friedlander DR, Margolis B et al. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr. Neurosurg.33(1), 49–55 (2000).
   PubMed Web of Science ®Google Scholar
• Liu TJ, LaFortune T, Honda T et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol. Cancer Ther.6(4), 1357–1367 (2007).
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Sakaida T, Saegusa T et al. Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int. J. Oncol.26(4), 993–998 (2005).
   Google Scholar
• Chan AY, Coniglio SJ, Chuang YY et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene24(53), 7821–7829 (2005).
   PubMed Web of Science ®Google Scholar
• Ding Q, Stewart J Jr, Prince CW et al. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res.62(18), 5336–5343 (2002).
   PubMed Web of Science ®Google Scholar
• Manning TJ Jr, Parker JC, Sontheimer H. Role of lysophosphatidic acid and rho in glioma cell motility. Cell Motil. Cytoskeleton45(3), 185–199 (2000).
   Google Scholar
• Salhia B, Rutten F, Nakada M et al. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res.65(19), 8792–8800 (2005).
   PubMedGoogle Scholar
• Malchinkhuu E, Sato K, Horiuchi Y et al. Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells. Oncogene24(44), 6676–6688 (2005).
   PubMedGoogle Scholar
• Annabi B, Bouzeghrane M, Moumdjian R, Moghrabi A, Beliveau R. Probing the infiltrating character of brain tumors: inhibition of RhoA/ROK-mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCg. J. Neurochem.94(4), 906–916 (2005).
   Google Scholar
• Joy AM, Beaudry CE, Tran NL et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J. Cell Sci.116(Pt 21), 4409–4417 (2003).
   PubMed Web of Science ®Google Scholar
• Hoelzinger DB, Mariani L, Weis J et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia7(1), 7–16 (2005).
   PubMed Web of Science ®Google Scholar
• Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T. Aberrant nuclear factor- κB activity and its participation in the growth of human malignant astrocytoma. J. Neurosurg.96(5), 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFκB pathway activation and BCL-XL/BCL-W expression. J. Biol. Chem.280(5), 3483–3492 (2005).
   PubMed Web of Science ®Google Scholar
• Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin. Cancer Res.12(24), 7261–7270 (2006).
   PubMed Web of Science ®Google Scholar
• Lal A, Glazer CA, Martinson HM et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res.62(12), 3335–3339 (2002).
   PubMed Web of Science ®Google Scholar
• Penar PL, Khoshyomn S, Bhushan A, Tritton TR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery40(1), 141–151 (1997).
   PubMed Web of Science ®Google Scholar
• Lamszus K, Brockmann MA, Eckerich C et al. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res.11(13), 4934–4940 (2005).
   PubMed Web of Science ®Google Scholar
• Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anticancer Ther.4(1), 105–128 (2004).
   PubMedGoogle Scholar
• Park CM, Park MJ, Kwak HJ et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res.66(17), 8511–8519 (2006).
   PubMed Web of Science ®Google Scholar
• Kubiatowski T, Jang T, Lachyankar MB et al. Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J. Neurosurg.95(3), 480–488 (2001).
   PubMed Web of Science ®Google Scholar
• Furukawa K, Kumon Y, Harada H et al. PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules. Int. J. Oncol.29(1), 73–81 (2006).
   PubMed Web of Science ®Google Scholar
• Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med.136(2), 261–276 (1972).
   PubMed Web of Science ®Google Scholar
• Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl.88, 169–177 (2003).
   PubMedGoogle Scholar
• Schiffer D, Chio A, Giordana MT, Mauro A, Migheli A, Vigliani MC. The vascular response to tumor infiltration in malignant gliomas. Morphometric and reconstruction study. Acta Neuropathol.77(4), 369–378 (1989).
   Google Scholar
• Wesseling P, van der Laak JA, de Leeuw H, Ruiter DJ, Burger PC. Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections. J. Neurosurg.81(6), 902–909 (1994).
   PubMed Web of Science ®Google Scholar
• Nagano N, Sasaki H, Aoyagi M, Hirakawa K. Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells. Acta Neuropathol.86(2), 117–125 (1993).
   PubMed Web of Science ®Google Scholar
• Sakariassen PO, Prestegarden L, Wang J et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc. Natl Acad. Sci. USA103(44), 16466–16471 (2006).
   PubMed Web of Science ®Google Scholar
• Pedersen PH, Edvardsen K, Garcia-Cabrera I et al. Migratory patterns of lac-z transfected human glioma cells in the rat brain. Int. J. Cancer62(6), 767–771 (1995).
   Google Scholar
• Kusters B, Leenders WP, Wesseling P et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res.62(2), 341–345 (2002).
   PubMed Web of Science ®Google Scholar
• Leenders W, Kusters B, Pikkemaat J et al. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int. J. Cancer105(4), 437–443 (2003).
   Google Scholar
• Leenders WP, Kusters B, Verrijp K et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res.10(18 Pt 1), 6222–6230 (2004).
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature423(6940), 593–595 (2003).
   PubMed Web of Science ®Google Scholar
• Steeg PS. Angiogenesis inhibitors: motivators of metastasis? Nat. Med.9(7), 822–823 (2003).
   PubMed Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA103(51), 19478–19483 (2006).
   PubMed Web of Science ®Google Scholar
• Levin V, Phuphanich S, Yung W et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J. Neurooncol.78(3), 295–302 (2006).
   PubMed Web of Science ®Google Scholar
• Groves M, Puduvalli V, Hess K et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol.20(5), 1383–1388 (2002).
   PubMed Web of Science ®Google Scholar
• Yung W, Albright R, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer83(5), 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncology7(4), 436–451 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Vande Woude G. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J. Cell. Biochem.88(2), 408–417 (2003).
   PubMed Web of Science ®Google Scholar
• Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Biochem. Int. J. Dev. Neurosci.17(5–6), 517–530 (1999).
   PubMed Web of Science ®Google Scholar
• Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery52(6), 1391–1399; discussion 1399 (2003).
   PubMed Web of Science ®Google Scholar
• Blouw B, Song H, Tihan T et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell4(2), 133–146 (2003).
   PubMed Web of Science ®Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio P. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell3(4), 347–361 (2003).
   PubMed Web of Science ®Google Scholar
• Brockmann M, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin. Cancer Res.9(12), 4578–4585 (2003).
   PubMed Web of Science ®Google Scholar
• Martens T, Schmidt NO, Eckerich C et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res.12(20 Pt 1), 6144–6152 (2006).
   PubMed Web of Science ®Google Scholar
• Burgess T, Coxon A, Meyer S et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res.66(3), 1721–1729 (2006).
   PubMed Web of Science ®Google Scholar
• Reardon D, Akabani G, Coleman R et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol.24(1), 115–122 (2006).
   PubMed Web of Science ®Google Scholar
• Wick W, Naumann U, Weller M. Transforming growth factor-β: a molecular target for the future therapy of glioblastoma. Curr. Pharm. Des.12(3), 341–349 (2006).
   PubMed Web of Science ®Google Scholar
• Bogdahn U, Mahapatra A, Olyushin V et al. A Phase IIb actively controlled study with the TGF-β-2 inhibitor AP 12009 for recurrent or refractory anaplastic astrocytoma. Presented at: The ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Hau P, Bogdahn U, Olyushin V et al. Results of a Phase IIb study in recurrent or refractory glioblastoma patients with the TGF-β-2 inhibitor AP 12009. Presented at: The ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Schlingensiepen K, Schlingensiepen R, Steinbrecher A et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev.17(1–2), 129–139 (2006).
   PubMed Web of Science ®Google Scholar
• Del Bufalo D, Ciuffreda L, Trisciuoglio D et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res.66(11), 5549–5554 (2006).
   PubMedGoogle Scholar
• Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res.60(6), 1541–1545 (2000).
   PubMed Web of Science ®Google Scholar
• Su J, Mayo L, Donner D, Durden D. PTEN and phosphatidylinositol 3´-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res.63(13), 3585–3592 (2003).
   PubMed Web of Science ®Google Scholar
• Das R, Mahabeleshwar G, Kundu G. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J. Biol. Chem.279(12), 11051–11064 (2004).
   PubMed Web of Science ®Google Scholar
• Lund CV, Nguyen MT, Owens GC et al. Reduced glioma infiltration in Src-deficient mice. J. Neurooncol.78(1), 19–29 (2006).
   PubMed Web of Science ®Google Scholar
• Angers-Loustau A, Hering R, Werbowetski TE, Kaplan DR, Del Maestro RF. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol. Cancer Res.2(11), 595–605 (2004).
   PubMed Web of Science ®Google Scholar
• Schittenhelm M, Shiraga S, Schroeder A et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res.66(1), 473–481 (2006).
   PubMed Web of Science ®Google Scholar
• Shor A, Keschman E, Lee F et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res.67(6), 2800–2808 (2007).
   PubMed Web of Science ®Google Scholar
• Alitalo K, Tammela T, Petrova T. Lymphangiogenesis in development and human disease. Nature438(7070), 946–953 (2005).
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin D, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell8(4), 299–309 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Harris S, Thorgeirsson U. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res.57(18), 3924–3928 (1997).
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen A et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J.18(2), 338–340 (2004).
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta P, Sgroi D et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell121(3), 335–348 (2005).
   PubMed Web of Science ®Google Scholar
• Glade Bender J, Cooney E, Kandel J, Yamashiro D. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist. Updat.7(4–5), 289–300 (2004).
   PubMed Web of Science ®Google Scholar
• Huang J, Soffer S, Kim E et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res.2(1), 36–42 (2004).
   PubMed Web of Science ®Google Scholar
• Yu J, Rak J, Coomber B, Hicklin D, Kerbel R. Effect of p53 status on tumor response to antiangiogenic therapy. Science295(5559), 1526–1528 (2002).
   PubMed Web of Science ®Google Scholar
• Jubb A, Oates A, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer6(8), 626–635 (2006).
   PubMed Web of Science ®Google Scholar
• Willett C, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med.10(2), 145–147 (2004).
   PubMed Web of Science ®Google Scholar
• Willett C, Boucher Y, Duda D et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J. Clin. Oncol.23(31), 8136–8139 (2005).
   PubMed Web of Science ®Google Scholar
• Jubb A, Hurwitz H, Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol.24(2), 217–227 (2006).
   PubMed Web of Science ®Google Scholar
• Ince W, Jubb A, Holden S et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl Cancer Inst.97(13), 981–989 (2005).
   PubMed Web of Science ®Google Scholar
• Duda D, Cohen K, di Tomaso E et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J. Clin. Oncol.24(9), 1449–1453 (2006).
   PubMed Web of Science ®Google Scholar
• Monestiroli S, Mancuso P, Burlini A et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res.61(11), 4341–4344 (2001).
   PubMed Web of Science ®Google Scholar
• Shaked Y, Emmenegger U, Man S et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood106(9), 3058–3061 (2005).
   PubMed Web of Science ®Google Scholar
• Peles E, Lidar Z, Simon A, Grossman R, Nass D, Ram Z. Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery55(3), 562–567; discussion 567–568 (2004).
   PubMed Web of Science ®Google Scholar
• Sampath P, Weaver C, Sungarian A, Cortez S, Alderson L, Stopa E. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Control11(3), 174–180 (2004).
   Google Scholar
• Drevs J, Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J. Intern. Med.260(6), 517–529 (2006).
   PubMed Web of Science ®Google Scholar
• Gulani V, Sundgren P. Diffusion tensor magnetic resonance imaging. J. Neuroophthalmol.26(1), 51–60 (2006).
   PubMedGoogle Scholar
• Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J. Clin. Oncol.24(20), 3293–3298 (2006).
   PubMed Web of Science ®Google Scholar
• Provenzale J. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am. J. Roentgenol.188(1), 11–23 (2007).
   Google Scholar
• Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology228(2), 523–532 (2003).
   PubMed Web of Science ®Google Scholar
• Chen EW, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with 18Ffluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol.25, 4714–4721 (2007).
   Google Scholar
• Rehman S, Jayson G. Molecular imaging of antiangiogenic agents. Oncologist10(2), 92–103 (2005).
   PubMed Web of Science ®Google Scholar
• Liang Y, Diehn M, Watson N et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl Acad. Sci. USA102(16), 5814–5819 (2005).
   PubMed Web of Science ®Google Scholar
• Maher E, Brennan C, Wen P et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res.66(23), 11502–11513 (2006).
   PubMed Web of Science ®Google Scholar
• Mischel P, Shai R, Shi T et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene22(15), 2361–2373 (2003).
   PubMed Web of Science ®Google Scholar
• Shai R, Shi T, Kremen T et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene22(31), 4918–4923 (2003).
   PubMed Web of Science ®Google Scholar
• Tso C, Freije W, Day A et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res.66(1), 159–167 (2006).
   PubMed Web of Science ®Google Scholar
• Karcher S, Steiner H, Ahmadi R et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int. J. Cancer118(9), 2182–2189 (2006).
   PubMed Web of Science ®Google Scholar
• Carlson MR, Pope WB, Horvath S et al. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin. Cancer Res.13(9), 2592–2598 (2007).
   Google Scholar
• Godard S, Getz G, Delorenzi M et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res.63(20), 6613–6625 (2003).
   PubMed Web of Science ®Google Scholar
• Freije W, Castro-Vargas F, Fang Z et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res.64(18), 6503–6510 (2004).
   PubMed Web of Science ®Google Scholar
• Rich J, Hans C, Jones B et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res.65(10), 4051–4058 (2005).
   PubMed Web of Science ®Google Scholar
• Singh S, Hawkins C, Clarke I et al. Identification of human brain tumour initiating cells. Nature432(7015), 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res.66(16), 7843–7848 (2006).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon R et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006).
   Google Scholar
• Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell11(1), 69–82 (2007).
   PubMed Web of Science ®Google Scholar